GlassScriptPhysician profile
Jennifer A Backus
NPI 1023503760
$9,053.51
in general payments reported to CMS, 2019-2025
35 companies · $2,547 in 2025
The $2,547 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,572 · 2022: $2,211 · 2023: $171 · 2024: $2,553 · 2025: $2,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,912 · Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,912.00 |
| Food and Beverage | $2,359.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $3,874.78 | 2021-2025 | |
| Lilly USA, LLC | $584.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $572.29 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $567.24 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Bigfoot Biomedical INC | $341.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $318.78 | 2021-2022 | |
| Corcept Therapeutics | $291.55 | 2021-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $274.61 | 2021-2025 | |
| Amgen INC. | $246.80 | 2021-2025 | Tepezza |
| Mannkind Corporation | $223.17 | 2025 | |
| Abbott Laboratories | $215.46 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $195.58 | 2021-2025 | Dexcom G6 Transmitter |
| Zealand Pharma US, INC. | $176.72 | 2021-2022 | |
| Medtronic, INC. | $163.10 | 2021-2022 | |
| Horizon Therapeutics Plc | $128.60 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $120.05 | 2025 | Isturisa |
| Abbvie INC. | $95.54 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.95 | 2022-2025 | Jardiance |
| Radius Health, INC. | $76.99 | 2021-2025 | Tymlos |
| Madrigal Pharmaceuticals | $75.42 | 2025 | Rezdiffra |
| Amphastar Pharmaceuticals, INC. | $48.95 | 2025 | |
| Clarus Therapeutics INC. | $48.40 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.33 | 2021 | |
| Cequr Corporation | $42.96 | 2022-2025 | Cequr Simplicity |
| Chiesi USA, INC. | $40.82 | 2025 | Myalept, Mycapssa |
| Amneal Pharmaceuticals LLC | $30.76 | 2022 | |
| Insulet Corporation | $28.25 | 2025 | Omnipod |
| Ipsen Biopharmaceuticals, INC | $22.26 | 2021 | |
| Amarin Pharma, INC. | $20.67 | 2021 | |
| Averitas Pharma INC. | $20.29 | 2025 | Qutenza |
| Boston Scientific Corporation | $19.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.49 | 2021 | |
| Antares Pharma, INC. | $13.53 | 2021 | |
| Ibsa Pharma INC. | $12.48 | 2022 | |
| Tandem Diabetes Care, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Backus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.